Results from Phase II testing of ProCyte Corp.'s wound healerIamin showed that the copper-peptide can increase closure ofdiabetic skin ulcers by 20 percent, the company said Thursday.
Two-week application of the drug achieved the increase in theaverage surface healed after it was injected into chronic legwounds in 17 patients.
The Kirkland, Wash., company (NASDAQ:PRCY) has a new,topical formulation of Iamin in a multicenter Phase II trial.
The stock lost 50 cents to $11.50 on Thursday.
(c) 1997 American Health Consultants. All rights reserved.